{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:43:20Z","timestamp":1770817400184,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11030-024-11081-7","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T10:31:49Z","timestamp":1734777109000},"page":"5561-5575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the role of pomalidomide in androgen-dependent prostate cancer: a computational analysis"],"prefix":"10.1007","volume":"29","author":[{"given":"Shivani","family":"Pathak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipendra Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun Kumar","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajanish","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"11081_CR1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48252","volume":"15","author":"M Al-Ghazawi","year":"2023","unstructured":"Al-Ghazawi M, Salameh H, Amo-Afful S et al (2023) An in-depth look into the epidemiological and etiological aspects of prostate cancer: a literature review. Cureus 15:e48252. https:\/\/doi.org\/10.7759\/cureus.48252","journal-title":"Cureus"},{"key":"11081_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.811044","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M et al (2022) Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. https:\/\/doi.org\/10.3389\/fpubh.2022.811044","journal-title":"Front Public Health"},{"key":"11081_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.22465\/juo.234600140007","volume":"21","author":"K Ito","year":"2023","unstructured":"Ito K, Kimura T (2023) Complex epidemiology of prostate cancer in Asian countries. Korean J Urol Oncol 21:5\u201313. https:\/\/doi.org\/10.22465\/juo.234600140007","journal-title":"Korean J Urol Oncol"},{"key":"11081_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2020.116397","volume":"272","author":"VK Singh","year":"2021","unstructured":"Singh VK, Pal R, Srivastava P et al (2021) Exposure of androgen mimicking environmental chemicals enhances proliferation of prostate cancer (LNCaP) cells by inducing AR expression and epigenetic modifications. Environ Pollut 272:116397. https:\/\/doi.org\/10.1016\/j.envpol.2020.116397","journal-title":"Environ Pollut"},{"key":"11081_CR5","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/cvr\/cvab241","volume":"118","author":"A Cittadini","year":"2022","unstructured":"Cittadini A, Isidori AM, Salzano A (2022) Testosterone therapy and cardiovascular diseases. Cardiovasc Res 118:2039\u20132057. https:\/\/doi.org\/10.1093\/cvr\/cvab241","journal-title":"Cardiovasc Res"},{"key":"11081_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A, Kelly GL (2023) BCL-2 protein family: attractive targets for cancer therapy. Apoptosis 28:20\u201338. https:\/\/doi.org\/10.1007\/s10495-022-01780-7","journal-title":"Apoptosis"},{"key":"11081_CR7","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.bbamcr.2019.05.003","volume":"1866","author":"Z Culig","year":"2019","unstructured":"Culig Z (2019) Epithelial mesenchymal transition and resistance in endocrine-related cancers. Biochimica et Biophysica Acta (BBA)\u2013Mol Cell Res 1866:1368\u20131375. https:\/\/doi.org\/10.1016\/j.bbamcr.2019.05.003","journal-title":"Biochimica et Biophysica Acta (BBA)\u2013Mol Cell Res"},{"key":"11081_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.865350","author":"J Huang","year":"2022","unstructured":"Huang J, Lin B, Li B (2022) Anti-androgen receptor therapies in prostate cancer: a brief update and perspective. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.865350","journal-title":"Front Oncol"},{"key":"11081_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.crchbi.2021.100006","volume":"1","author":"N Upadhyay","year":"2021","unstructured":"Upadhyay N, Tilekar K, Hess JD et al (2021) Benefits and pitfalls: Epigenetic modulators in prostate cancer intervention. Curr Res Chem Biol 1:100006. https:\/\/doi.org\/10.1016\/j.crchbi.2021.100006","journal-title":"Curr Res Chem Biol"},{"key":"11081_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000447176","volume":"10","author":"S Tonyali","year":"2017","unstructured":"Tonyali S, Haberal HB, Sogutdelen E (2017) Toxicity, adverse events, and quality of life associated with the treatment of metastatic castration-resistant prostate cancer. Curr Urol 10:169\u2013173. https:\/\/doi.org\/10.1159\/000447176","journal-title":"Curr Urol"},{"key":"11081_CR11","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2019.27.2.59","author":"K Park","year":"2019","unstructured":"Park K (2019) A review of computational drug repurposing. Transl Clin Pharmacol. https:\/\/doi.org\/10.12793\/tcp.2019.27.2.59","journal-title":"Transl Clin Pharmacol"},{"key":"11081_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/wsbm.1337","volume":"8","author":"RA Hodos","year":"2016","unstructured":"Hodos RA, Kidd BA, Shameer K et al (2016) In silico methods for drug repurposing and pharmacology. WIREs Syst Biol Med 8:186\u2013210. https:\/\/doi.org\/10.1002\/wsbm.1337","journal-title":"WIREs Syst Biol Med"},{"key":"11081_CR13","first-page":"3","volume-title":"Drug repurposing hypothesis molecular aspects and therapeutic applications","author":"M Rudrapal","year":"2020","unstructured":"Rudrapal M, Khairnar SJ, Jadhav AG (2020) Drug repurposing (DR): An emerging approach in drug discovery. In: Badria FA (ed) Drug repurposing hypothesis molecular aspects and therapeutic applications. IntechOpen, pp 3\u201322"},{"key":"11081_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.rdc.2022.08.006","volume":"49","author":"D Minhas","year":"2023","unstructured":"Minhas D, Nidhaan A, Husni ME (2023) Recommendations for the use of nonsteroidal anti-inflammatory drugs and cardiovascular disease risk. Rheum Dis Clin North Am 49:179\u2013191. https:\/\/doi.org\/10.1016\/j.rdc.2022.08.006","journal-title":"Rheum Dis Clin North Am"},{"key":"11081_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/1055-9965.EPI-19-0792","volume":"30","author":"W Tang","year":"2021","unstructured":"Tang W, Fowke JH, Hurwitz LM et al (2021) Aspirin use and prostate cancer among African-American men in the southern community cohort study. Cancer Epidemiol Biomark Prev 30:539\u2013544. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0792","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"11081_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100267","volume":"26","author":"SN Joshi","year":"2021","unstructured":"Joshi SN, Murphy EA, Olaniyi P, Bryant RJ (2021) The multiple effects of aspirin in prostate cancer patients. Cancer Treat Res Commun 26:100267. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100267","journal-title":"Cancer Treat Res Commun"},{"key":"11081_CR17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2174\/1568026623666230130150029","volume":"23","author":"SM Sousa","year":"2023","unstructured":"Sousa SM, Xavier CPR, Vasconcelos MH, Palmeira A (2023) Repurposing some of the well-known Non-steroid Anti-inflammatory drugs (NSAIDs) for cancer treatment. Curr Top Med Chem 23:1171\u20131195. https:\/\/doi.org\/10.2174\/1568026623666230130150029","journal-title":"Curr Top Med Chem"},{"key":"11081_CR18","doi-asserted-by":"publisher","first-page":"9698","DOI":"10.1038\/srep09698","volume":"5","author":"M Guan","year":"2015","unstructured":"Guan M, Su L, Yuan Y-C et al (2015) Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer. Sci Rep 5:9698. https:\/\/doi.org\/10.1038\/srep09698","journal-title":"Sci Rep"},{"key":"11081_CR19","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.6153.2","author":"T Koltai","year":"2015","unstructured":"Koltai T (2015) Fenofibrate in cancer: mechanisms involved in anticancer activity. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.6153.2","journal-title":"F1000Res"},{"key":"11081_CR20","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.2174\/1568026616666160216153618","volume":"16","author":"D Bhattarai","year":"2016","unstructured":"Bhattarai D, Singh S, Jang Y et al (2016) An insight into drug repositioning for the development of novel anti-cancer drugs. Curr Top Med Chem 16:2156\u20132168. https:\/\/doi.org\/10.2174\/1568026616666160216153618","journal-title":"Curr Top Med Chem"},{"key":"11081_CR21","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7562","author":"A Allegra","year":"2020","unstructured":"Allegra A, Innao V, Allegra A et al (2020) Antitumorigenic action of nelfinavir: effects on multiple myeloma and hematologic malignancies (Review). Oncol Rep. https:\/\/doi.org\/10.3892\/or.2020.7562","journal-title":"Oncol Rep"},{"key":"11081_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","volume":"17","author":"J Kim","year":"2010","unstructured":"Kim J, Tang JY, Gong R et al (2010) Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell 17:388\u2013399. https:\/\/doi.org\/10.1016\/j.ccr.2010.02.027","journal-title":"Cancer Cell"},{"key":"11081_CR23","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3892\/ol.2017.6325","volume":"14","author":"H Tsubamoto","year":"2017","unstructured":"Tsubamoto H, Ueda T, Inoue K et al (2017) Repurposing itraconazole as an anticancer agent. Oncol Lett 14:1240\u20131246. https:\/\/doi.org\/10.3892\/ol.2017.6325","journal-title":"Oncol Lett"},{"key":"11081_CR24","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-09-1035","volume":"15","author":"K Iljin","year":"2009","unstructured":"Iljin K, Ketola K, Vainio P et al (2009) High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 15:6070\u20136078. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1035","journal-title":"Clin Cancer Res"},{"key":"11081_CR25","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1158\/1535-7163.MCT-17-0157","volume":"16","author":"HB Bin","year":"2017","unstructured":"Bin HB, Ganju A, Sikander M et al (2017) Ormeloxifene suppresses prostate tumor growth and metastatic phenotypes via inhibition of oncogenic \u03b2-catenin signaling and EMT progression. Mol Cancer Ther 16:2267\u20132280. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0157","journal-title":"Mol Cancer Ther"},{"key":"11081_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00500","author":"B Turanli","year":"2018","unstructured":"Turanli B, Gr\u00f8tli M, Boren J et al (2018) Drug repositioning for effective prostate cancer treatment. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2018.00500","journal-title":"Front Physiol"},{"key":"11081_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A (2019) Erdafitinib: first global approval. Drugs 79:1017\u20131021. https:\/\/doi.org\/10.1007\/s40265-019-01142-9","journal-title":"Drugs"},{"key":"11081_CR28","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH et al (2023) Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med 389:1961\u20131971. https:\/\/doi.org\/10.1056\/NEJMoa2308849","journal-title":"N Engl J Med"},{"key":"11081_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00733","author":"W Cui","year":"2020","unstructured":"Cui W, Aouidate A, Wang S et al (2020) Discovering anti-cancer drugs via computational methods. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2020.00733","journal-title":"Front Pharmacol"},{"key":"11081_CR30","doi-asserted-by":"publisher","first-page":"79750","DOI":"10.18632\/oncotarget.19336","volume":"8","author":"M Cho","year":"2017","unstructured":"Cho M, Gong J, Frankel P et al (2017) A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. Oncotarget 8:79750\u201379760. https:\/\/doi.org\/10.18632\/oncotarget.19336","journal-title":"Oncotarget"},{"key":"11081_CR31","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2011.1270","author":"C Festuccia","year":"2011","unstructured":"Festuccia C (2011) Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2011.1270","journal-title":"Int J Oncol"},{"key":"11081_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115212","volume":"165","author":"N El Omari","year":"2023","unstructured":"El Omari N, Bakrim S, Khalid A et al (2023) Anticancer clinical efficiency and stochastic mechanisms of belinostat. Biomed Pharmacother 165:115212. https:\/\/doi.org\/10.1016\/j.biopha.2023.115212","journal-title":"Biomed Pharmacother"},{"key":"11081_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1158\/1538-7445.AM2022-651","volume":"82","author":"T Sugawara","year":"2022","unstructured":"Sugawara T, NGuyen H, Corey E et al (2022) Abstract 651: combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models. Cancer Res 82:651\u2013651. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-651","journal-title":"Cancer Res"},{"key":"11081_CR34","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.2147\/CMAR.S353411","volume":"14","author":"MS Wu","year":"2022","unstructured":"Wu MS, Goldberg H (2022) Role of rucaparib in the treatment of prostate cancer: clinical perspectives and considerations. Cancer Manag Res 14:3159\u20133174. https:\/\/doi.org\/10.2147\/CMAR.S353411","journal-title":"Cancer Manag Res"},{"key":"11081_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1006101","author":"AE Harris","year":"2022","unstructured":"Harris AE, Metzler VM, Lothion-Roy J et al (2022) Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2022.1006101","journal-title":"Front Endocrinol (Lausanne)"},{"key":"11081_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN et al (2023) Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med 388:719\u2013732. https:\/\/doi.org\/10.1056\/NEJMoa2214676","journal-title":"N Engl J Med"},{"key":"11081_CR37","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.3390\/cancers3033449","volume":"3","author":"RJ Amato","year":"2011","unstructured":"Amato RJ, Glode LM, Podolnick J et al (2011) Phase II study of pomalidomide in patients with castration-resistant prostate cancer. Cancers (Basel) 3:3449\u20133460. https:\/\/doi.org\/10.3390\/cancers3033449","journal-title":"Cancers (Basel)"},{"key":"11081_CR38","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B et al (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98\u2013W102. https:\/\/doi.org\/10.1093\/nar\/gkx247","journal-title":"Nucleic Acids Res"},{"key":"11081_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00068","author":"H Zheng","year":"2020","unstructured":"Zheng H, Zhang G, Zhang L et al (2020) Comprehensive review of web servers and bioinformatics tools for cancer prognosis analysis. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.00068","journal-title":"Front Oncol"},{"key":"11081_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2288-10-20","volume":"10","author":"CA Bellera","year":"2010","unstructured":"Bellera CA, MacGrogan G, Debled M et al (2010) Variables with time-varying effects and the cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol 10:20. https:\/\/doi.org\/10.1186\/1471-2288-10-20","journal-title":"BMC Med Res Methodol"},{"key":"11081_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2273440","author":"VK Singh","year":"2023","unstructured":"Singh VK, Thakur DC, Rajak N et al (2023) The multi-protein targeting potential of bioactive syringin in inflammatory diseases: using molecular modelling and in-silico analysis of regulatory elements. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2023.2273440","journal-title":"J Biomol Struct Dyn"},{"key":"11081_CR42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10822-010-9349-1","volume":"24","author":"JR Greenwood","year":"2010","unstructured":"Greenwood JR, Calkins D, Sullivan AP, Shelley JC (2010) Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J Comput Aided Mol Des 24:591\u2013604. https:\/\/doi.org\/10.1007\/s10822-010-9349-1","journal-title":"J Comput Aided Mol Des"},{"key":"11081_CR43","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212ligand complexes. J Med Chem 49:6177\u20136196. https:\/\/doi.org\/10.1021\/jm051256o","journal-title":"J Med Chem"},{"key":"11081_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.991369","volume":"10","author":"U Dasmahapatra","year":"2022","unstructured":"Dasmahapatra U, Kumar CK, Das S et al (2022) In-silico molecular modelling, MM\/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo[4,5-c]quinolines as potential anti-tumor agents. Front Chem 10:991369. https:\/\/doi.org\/10.3389\/fchem.2022.991369","journal-title":"Front Chem"},{"key":"11081_CR45","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1080\/07391102.2023.2216299","volume":"42","author":"VK Singh","year":"2024","unstructured":"Singh VK, Thakur DC, Rajak N et al (2024) Immunomodulatory potential of bioactive glycoside syringin: a network pharmacology and molecular modeling approach. J Biomol Struct Dyn 42:3906\u20133919. https:\/\/doi.org\/10.1080\/07391102.2023.2216299","journal-title":"J Biomol Struct Dyn"},{"key":"11081_CR46","unstructured":"Frisch M, Trucks G, Schlegel H, et al (2009) Gaussian 09 (Revision A02). Gaussian Inc Wallingford CT"},{"key":"11081_CR47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/ijmr.IJMR_1132_20","volume":"153","author":"S Behera","year":"2021","unstructured":"Behera S, Mahapatra N, Tripathy C, Pati S (2021) Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: an in silico approach. Indian J Med Res 153:132. https:\/\/doi.org\/10.4103\/ijmr.IJMR_1132_20","journal-title":"Indian J Med Res"},{"key":"11081_CR48","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.molstruc.2017.10.075","volume":"1154","author":"CS Manohar","year":"2018","unstructured":"Manohar CS, Manikandan A, Sridhar P et al (2018) Drug repurposing of novel quinoline acetohydrazide derivatives as potent COX-2 inhibitors and anti-cancer agents. J Mol Struct 1154:437\u2013444. https:\/\/doi.org\/10.1016\/j.molstruc.2017.10.075","journal-title":"J Mol Struct"},{"key":"11081_CR49","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"key":"11081_CR50","doi-asserted-by":"publisher","first-page":"23795","DOI":"10.1038\/s41598-024-75059-z","volume":"14","author":"H Saini","year":"2024","unstructured":"Saini H, Gupta PK, Mahapatra AK et al (2024) Deciphering the multi-scale mechanism of herbal phytoconstituents in targeting breast cancer: a computational pharmacological perspective. Sci Rep 14:23795. https:\/\/doi.org\/10.1038\/s41598-024-75059-z","journal-title":"Sci Rep"},{"key":"11081_CR51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar DS, Karthikeyan SK, Korla PK et al (2022) UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25:18\u201327. https:\/\/doi.org\/10.1016\/j.neo.2022.01.001","journal-title":"Neoplasia"},{"key":"11081_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2024.1482852","author":"A Shahi","year":"2024","unstructured":"Shahi A, Manhas R, Bhattacharya S et al (2024) Synthesis and antibacterial potential of novel thymol derivatives against methicillin-resistant Staphylococcus aureus and P. aeruginosa pathogenic bacteria. Front Chem. https:\/\/doi.org\/10.3389\/fchem.2024.1482852","journal-title":"Front Chem"},{"key":"11081_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.133651","volume":"1268","author":"A Zochedh","year":"2022","unstructured":"Zochedh A, Priya M, Shunmuganarayanan A et al (2022) Investigation on structural, spectroscopic, DFT, biological activity and molecular docking simulation of essential oil Gamma-Terpinene. J Mol Struct 1268:133651. https:\/\/doi.org\/10.1016\/j.molstruc.2022.133651","journal-title":"J Mol Struct"},{"key":"11081_CR54","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1016\/j.matpr.2016.11.025","volume":"3","author":"J Prashanth","year":"2016","unstructured":"Prashanth J, Ramesh G, Laxman Naik J et al (2016) Molecular geometry, NBO analysis, hyperpolarizability and HOMO-LUMO energies of 2-azido-1-phenylethanone using quantum chemical calculations. Mater Today Proc 3:3761\u20133769. https:\/\/doi.org\/10.1016\/j.matpr.2016.11.025","journal-title":"Mater Today Proc"},{"key":"11081_CR55","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/ajoc.201200103","volume":"1","author":"L Zhuo","year":"2012","unstructured":"Zhuo L, Liao W, Yu Z (2012) A frontier molecular orbital theory approach to understanding the Mayr equation and to quantifying nucleophilicity and electrophilicity by using HOMO and LUMO energies. Asian J Org Chem 1:336\u2013345. https:\/\/doi.org\/10.1002\/ajoc.201200103","journal-title":"Asian J Org Chem"},{"key":"11081_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/hc-2020-0118","volume":"27","author":"M Beytur","year":"2021","unstructured":"Beytur M, Avinca I (2021) Molecular, electronic, nonlinear optical and spectroscopic analysis of heterocyclic 3-substituted-4-(3-methyl-2-thienylmethyleneamino)-4,5-dihydro-1 H -1,2,4-triazol-5-ones: experiment and DFT calculations. Heterocycl Comm 27:1\u201316. https:\/\/doi.org\/10.1515\/hc-2020-0118","journal-title":"Heterocycl Comm"},{"key":"11081_CR57","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1021\/ic00277a030","volume":"27","author":"RG Pearson","year":"1988","unstructured":"Pearson RG (1988) Absolute electronegativity and hardness: application to inorganic chemistry. Inorg Chem 27:734\u2013740. https:\/\/doi.org\/10.1021\/ic00277a030","journal-title":"Inorg Chem"},{"key":"11081_CR58","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jrs.2788","volume":"42","author":"C Ravikumar","year":"2011","unstructured":"Ravikumar C, Hubert Joe I (2011) Structural and nonlinear optical properties of cross-conjugated system benzophenone thiosemicarbazone: a vibrational spectroscopic study. J Raman Spectrosc 42:815\u2013824. https:\/\/doi.org\/10.1002\/jrs.2788","journal-title":"J Raman Spectrosc"},{"key":"11081_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.131585","volume":"1249","author":"LM Novena","year":"2022","unstructured":"Novena LM, Athimoolam S, Anitha R, Bahadur SA (2022) Synthesis, crystal structure, hirshfeld surface analysis, spectral and quantum chemical studies of pharmaceutical cocrystals of a bronchodilator drug (Theophylline). J Mol Struct 1249:131585. https:\/\/doi.org\/10.1016\/j.molstruc.2021.131585","journal-title":"J Mol Struct"},{"key":"11081_CR60","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.jiph.2022.10.013","volume":"15","author":"MB Singh","year":"2022","unstructured":"Singh MB, Sharma R, Kumar D et al (2022) An understanding of coronavirus and exploring the molecular dynamics simulations to find promising candidates against the Mpro of nCoV to combat the COVID-19: a systematic review. J Infect Public Health 15:1326\u20131349. https:\/\/doi.org\/10.1016\/j.jiph.2022.10.013","journal-title":"J Infect Public Health"},{"key":"11081_CR61","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1021\/acs.jcim.1c00198","volume":"61","author":"A Ongaro","year":"2021","unstructured":"Ongaro A, Oselladore E, Memo M et al (2021) Insight into the LFA-1\/SARS-CoV-2 Orf7a complex by protein-protein docking, molecular dynamics, and MM-GBSA calculations. J Chem Inf Model 61:2780\u20132787. https:\/\/doi.org\/10.1021\/acs.jcim.1c00198","journal-title":"J Chem Inf Model"},{"key":"11081_CR62","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/jcb.25928","volume":"118","author":"H Liu","year":"2017","unstructured":"Liu H, Wang L, Tian J et al (2017) Molecular dynamics studies on the enzalutamide resistance mechanisms induced by androgen receptor mutations. J Cell Biochem 118:2792\u20132801. https:\/\/doi.org\/10.1002\/jcb.25928","journal-title":"J Cell Biochem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11081-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-11081-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11081-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:28:51Z","timestamp":1763728131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-11081-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11081"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-11081-7","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}